Furthermore, autophagy abolition through the ATG5/7 re-sensitized EC109/CDDP knockdown or the use of pharmacological inhibitors is greatly significant [36] not only in the esophageal, but also in gastric [37], colorectal [38, 39], bladder [40], ovarian [41], and prostate cancers [42]. This evidence concerns the gene ATG5 and prostate cancer.